Treating Later-Line Multiple Myeloma With CAR T-Cell Therapy

Early Relapse Guides Use of CAR T vs Other Options in LBCL

During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell therapy, autologous stem cell therapy, or other treatment options.

Bridging and BCMA Exposure Impact Ide-Cel Outcomes in Multiple Myeloma

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients receiving ide-cel in terms of bridging therapy, quality of life, and prior BCMA therapy.

PFS Benefit of Ide-cel in Myeloma Maintained in Higher-Risk Population

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with relapsed/refractory multiple myeloma.

Analyzing Ide-cel’s Trade-offs of Efficacy and Toxicity in Myeloma

During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory multiple myeloma.

Usmani Projects a Future of CAR T in Community for Myeloma and Other Cancers

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR T-cell therapies in multiple myeloma and beyond.

CAR T and CRS Adverse Events Considered in Relapsed Multiple Myeloma

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for a patient with relapsed/refractory multiple myeloma and relevance of the KarMMa-3 trial for their treatment.

Referral for CAR T Should Always Be Considered in R/R Multiple Myeloma

Kenneth Shain, MD, PhD, discusses why he recommends most patients with relapsed/refractory multiple myeloma be referred for evaluation to receive chimeric antigen receptor T-cell therapy.

Efficacy and Treatment-Free Interval Support Earlier Use of CAR T in R/R Myeloma

Kenneth Shain, MD, PhD, discusses the rationale for giving chimeric antigen receptor (CAR) T-cell therapy in earlier lines of therapy for relapsed/refractory (R/R) multiple myeloma.

Ide-cel Shows Efficacy Earlier in R/R Multiple Myeloma Despite Crossover

During a Case-Based Roundtable® event, Surbhi Sidana, MD, discussed the KarMMa-3 trial of earlier-line CAR T-cell therapy in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.

How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma

During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.

CAR T-Cell Therapy Significantly Impacts R/R Multiple Myeloma

During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the benefits of using CAR T-cell therapy in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.

Updated Trial and Real-World Data Show Benefit of Ide-Cel for Multiple Myeloma

Abdullah M. Khan, MBBS, discusses the recent updates to data on the use of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.